Dr. Abraham (Bram) Bout is Chief Executive Officer and Managing Director of Bioceros, a division of the Polpharma Group. Recently, Bram was VP, Head of Epirus Biopharmaceuticals (Netherlands). He was also Chief Technology Officer at Profibrix BV (Leiden, The Netherlands) from 2007 – 2014. Prior to joining Bioceros (in 2007), he was employed by Crucell (from 1993 till March 2007), where he held several management positions with increasing responsibility. His last position at Crucell was Vice President, Protein Production. Bram is co-inventor of the human PER.C6 production platform which is used for the development and manufacturing of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy products. He studies Chemistry at the University of Amsterdam and his PhD thesis was on peroxisomal storage disorders. He published over 50 scientific articles and is co-inventor on 90 patents about the PER.C6 cell line technology and in the field of recombinant protein production and gene therapy.
CSO, Managing Director
Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. He also carried out post-doctoral positions at University of Amsterdam at the Department of Anatomy and Embryology and at the Department of Clinical Epidemiology. Thereafter he was one of the founders of PanGenetics where he was responsible for project management and animal studies. Since the merger between PanGenetics and Tanox Inc. in Houston, he had the position of VP Preclinical in which he was world-wide responsible for preclinical safety assessments and animals studies for the Tanox group. Dr. Boon has performed antibody therapy for immunoinflammatory diseases both in murine and non-human primate disease models and healthy non-human primates. Thereafter Dr. Boon was one of the founders of MacroZyme BV and for 2 years Director of Preclinical R&D of MacroZyme BV, where he was responsible for a small molecule project in the metabolic field and various potential protein-based therapeutic molecules. In 2003 he was one of the founders of Bioceros BV where he currently holds a position of Chief Scientific Officer (CSO). In addition he held a position as CSO for 4AZA Bioscience NV and VP Preclinical (ad interim) for PanGenetics BV until the end of 2006. He has extensive experience in molecular and cellular immunology and in therapeutic antibody development and has been involved in the trajectory of preclinical preparation and design of First into Man studies using therapeutic antibodies. Dr. Boon is author/co-author of over 200 papers in international scientific journals in the field of medical biotechnology.
COO, Managing Director
Remco Brandt holds a Master of Science degree in Management and held several scientific and management positions over the last decades in both Academic institutions and biotech companies in the Netherlands, Germany and the US. He was closely involved in the set up of several new life science laboratories and biotech companies. He has a broad experience in operations, administration, HR and finance specifically for biotech-oriented organizations. Most recently he was VP Business Operations and managing director of Epirus Biopharmaceuticals (Netherlands) BV, part of Nasdaq listed biopharmaceutical company EPIRUS Biopharmaceuticals Inc. Besides founder of Bioceros, he is also founder/managing director of Life Science Purchasing Power BV, BiocerOX Products, Ambracia Biopharmaceuticals and Cluster Therapeutics.
EMILE VAN CORVEN
Dr. Emile van Corven is Chief Development Officer at Bioceros, Head of Downstream Process and Analytical development at Bioceros. Prior to joining Bioceros he was a principal consultant CMC at Xendo (2014-2015). From 2001-2014 he was employed by Crucell/J&J, where he was responsible for the USP and DSP development of MAbs and viral vaccines, and the GMP pilot plant (global). From 2000-2001 he worked for the Dutch regulatory authorities as head of control lab for the release blood products/vaccines on the European market, and head of a regulatory group for the review of CMC dossiers biological/biotechnological products for access to the European market. From 1992-2000 he worked for Pharming, where he held various positions with increasing responsibility in pharmaceutical development or recombinant proteins (DSP, analytical, Tech transfer, GMP) and project management. From 1988-1992 he was a post-doc at The Netherlands Cancer Institute in Amsterdam. He got his PhD in 1987 at Nijmegen University, and his MSc in biology/chemistry at Leiden university in 1983. He published over 30 peer-reviewed scientific articles and is co-inventor on various patents. He was member of accreditation commission to assess the quality of the PDEng program “Bioproduct designer”, Technical University Delft, Netherlands. From 2012-2015 he was member of the editorial board of “Pharmaceutical Bioprocessing” journal.